The short answer
Ginkgo supplements deserve review while taking dasatinib, especially if you have low platelets, bleeding symptoms or other medicines that affect clotting. The concern is precautionary; a direct increase in bleeding from this exact combination has not been measured.
What this answer covers
Oral dasatinib with ginkgo supplements; exact dose, preparation and other bleeding risks matter.
- Supplement or preparation
- Ginkgo biloba
- Medication ingredient
- dasatinib
Check the exact treatment
This review concerns oral dasatinib tablets. Conventional tablets and PHYRAGO contain the same active ingredient but can differ in their response to acid-reducing medicines. Keep the exact prescribed product and have its directions checked before changing a supplement or antacid.
Why the combination needs review
Dasatinib can cause serious bleeding. Ginkgo leaf medicines carry a bleeding precaution; seed products or unrelated preparations are not equivalent. No exact-pair study establishes how much additional risk a particular product creates.
The human evidence is not uniform
A short study of a defined ginkgo leaf extract with aspirin found no additional bleeding-time or platelet effect compared with aspirin alone. It involved healthy volunteers and a different drug, so it cannot establish safety during dasatinib-related low platelet counts.
Use symptoms and the treatment plan
Show the oncology team the product, dose and other medicines before starting it. Report unusual bruising or persistent bleeding; seek urgent care for major bleeding, black stools or vomiting blood. Do not rely on dose spacing or stop the cancer medicine yourself. Follow the blood-count and monitoring plan.
Evidence and practical considerations
Side effects & toxicity
The drug’s bleeding warning and supplement-specific guidance support conditional review while human counterevidence limits a universal causal claim.
- Exact scope
- Oral dasatinib with ginkgo supplements; exact dose, preparation and other bleeding risks matter. with RxNorm 475342 IN dasatinib. Current exact oral product: Dasatinib oral monohydrate tablets. Salt/formulation named explicitly; no transfer to unrelated drugs or routes.
- Medication form and route
- Oral
What remains uncertain
- No exact co-use bleeding-outcome trial. Supplement guidance and drug warning are a conditional bridge; proxy tests and different-drug null results retained.
Factors that may matter: Exact oral formulation and supplement preparation; Drug exposure versus clinical outcomes; Dose, duration and other medicines; Individual monitoring plan.
Read the supporting source summaries
Source 1: Current original prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the exact oral formulation.
Antacids two hours apart; avoid strong CYP3A inducers; bleeding and thrombocytopenia warnings.
How this applies: RxNorm 475342 IN dasatinib. Current exact oral product: Dasatinib oral monohydrate tablets. Salt/formulation named explicitly; no transfer to unrelated drugs or routes.
Exact current oral product source, not a clinical trial of every supplement. Formulation, dose, population and mechanism remain explicit.
Source 2: Original official botanical monograph
ema.europa.eu · Source check Sep 10, 2026
Population: Users of defined leaf medicines.
Bleeding susceptibility and concomitant antiplatelet/anticoagulant use require review.
How this applies: Conditional preparation-specific bleeding precaution.
No exact dasatinib trial; seed or other species not equivalent.
Source 3: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 50 healthy men in crossover.
No additional bleeding-time or platelet/coagulation effect detected.
How this applies: Exact reported preparation, population and endpoints; transfer to dasatinib explicitly limited.
Abstract-only short healthy trial with different drug; cannot establish safety with dasatinib-related thrombocytopenia.
Source 4: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 10, 2026
Population: Terminology.
dasatinib is IN.
How this applies: Exact ingredient.
Not clinical evidence.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Sources checked and article drafted. |
Article revision: 2693b1a373b5120d
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.